Director of New Hope Cancer Center, Beijing, China

Hematology

Dr. Derick H. Lau, MD

Derick H. Lau works in the field of Hematology. He went to University of Missouri-Columbia School of Medicine. Derick is also a published physician. He has 25 paper published. The most recent paper is: Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors.

Publications

Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid Tumors.
Quality of Life Among Long-Term Survivors of Head and Neck Cancer Treated by Intensity-Modulated Radiotherapy.
Feasibility and toxicity of concurrent chemoradiation for elderly patients with head and neck Cancer.
Differential response rates to irradiation among patients with human papillomavirus positive and negative oropharyngeal Cancer.
Brachial Plexus-Associated Neuropathy After High-Dose Radiation Therapy for Head-and-Neck Cancer.
A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid Cancers: a ...
Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid Tumors.
Voice quality after organ-preservation therapy with definitive radiotherapy for laryngeal Cancer.
Tobacco smoking during radiation therapy for head-and-neck Cancer is associated with unfavorable outcome.
Primary radiation therapy for head-and-neck Cancer in the setting of human immunodeficiency virus.
Evaluating the role of prophylactic gastrostomy tube placement prior to definitive chemoradiotherapy for head and neck Cancer.
Radiation therapy in the management of head-and-neck Cancer of unknown primary origin: how does the addition of concurrent chemotherapy affect the therapeutic ratio?
Escalating weekly doses of cetuximab and correlation with skin toxicity: A phase I study.
Late esophageal toxicity after radiation therapy for head and neck Cancer.
Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung Cancer.
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung Cancer: a California Cancer Consortium Phase I study.
Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung Cancer.
Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung Cancer: biologic rationale for combination strategies.
Identification of novel targeting peptides for human ovarian Cancer cells using "one-bead one-compound" combinatorial libraries.
An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of Cancer clinical trial costs in California.
Treatment of extensive small cell lung Cancer.
Predictive molecular markers: has the time come for routine use in lung Cancer?
Population-based maximum tolerated dose of irinotecan and carboplatin.
Contributions of mouse biology to breast Cancer research.

Schools

University Of MissouriColumbia School Of Medicine
Valley Med Center
Stanford University

Conditions Treated

Adrenal Gland Cancer
Anemia
Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
Brain Cancer
View All

Doctors Specialties

Medical Oncology
Oncology
Hematology

Accepted Insurances

Education

University of California Davis
Stanford University
University of Missouri-Columbia School of Medicine

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. Shahzad A. Siddique, MD This Doctor is OpenDoctor Recommended.
	Dr. Michael P. Carroll, MD This Doctor is OpenDoctor Recommended.
	Dr. Richard M. Guy, MD This Doctor is OpenDoctor Recommended.
	Dr. Hoa C. Duong, MD This Doctor is OpenDoctor Recommended.
	Dr. Colin P. Spears, MD This Doctor is OpenDoctor Recommended.
	Dr. Mehrdad Abedi, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Kim A. Deckard-Janatpour, MD
	Dr. James D. Kim, MD